| 39.9 -0.74 (-1.82%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 58.41 |
1-year : | 66.45 |
| Resists | First : | 50.01 |
Second : | 56.9 |
| Pivot price | 43.54 |
|||
| Supports | First : | 38.87 |
Second : | 32.34 |
| MAs | MA(5) : | 40.52 |
MA(20) : | 44.98 |
| MA(100) : | 50.32 |
MA(250) : | 46.17  |
|
| MACD | MACD : | -3.2 |
Signal : | -2.8 |
| %K %D | K(14,3) : | 8.7 |
D(3) : | 6 |
| RSI | RSI(14): 28.4 |
|||
| 52-week | High : | 61.75 | Low : | 27.06 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SRRK ] has closed above bottom band by 20.7%. Bollinger Bands are 23.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41 - 41.22 | 41.22 - 41.41 |
| Low: | 38.19 - 38.5 | 38.5 - 38.76 |
| Close: | 39.43 - 39.9 | 39.9 - 40.29 |
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Sat, 17 Oct 2026
How Investors May Respond To Scholar Rock Holding (SRRK) EMA Refile - Simply Wall Street
Fri, 16 Oct 2026
Scholar Rock Holding Corporation (SRRK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 16 Oct 2026
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - www.marketscreener.com
Thu, 15 Oct 2026
EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK) - Yahoo Finance
Thu, 15 Oct 2026
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing - Stocktwits
Sun, 11 Oct 2026
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 122 (M) |
| Shares Float | 104 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 117.5 (%) |
| Shares Short | 22,720 (K) |
| Shares Short P.Month | 18,010 (K) |
| EPS | -3.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.9 % |
| Return on Equity (ttm) | -167.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.71 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -297 (M) |
| Levered Free Cash Flow | -154 (M) |
| PE Ratio | -12.02 |
| PEG Ratio | 0 |
| Price to Book value | 19.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|